Researchers at Stanford University's Curtis Laboratory have used gene expression to categorize the sensitivity and resistance of anthracycline chemotherapy in breast cancer patients with utmost precision.
Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.
Researchers at Stanford have leveraged spatial proteomic analysis to identify biomarkers with immediate implications for HER2-positive breast cancer treatment decision making and patient stratification.
Researchers at Stanford have developed methods of diagnosing and treating colorectal cancer based on the discovery of genetic aberrations indicative of a patient's risk of metastasis.
Stanford inventors have developed and fabricated biodegradable and biocompatible polysaccharide hydrogel optical fibers for fiber optic sensing and light transmission in biomedical applications like antigen detection, tracking cellular events, and optogenetics.
Stanford researchers have formulated a statistical model to determine the risk of breast cancer recurrence with unprecedented accuracy in women 5 – 20 years after initial diagnosis.
Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.
Stanford researchers in the Goldberg lab have discovered two novel gene therapy targets for the treatment of glaucoma and other optic neuropathies. Glaucoma is the leading cause of irreversible blindness world-wide, affecting millions of adults in the United States alone.
Stanford inventors have developed TrueImage, a machine learning algorithm to assess the quality of patient images sent in for telemedicine appointments.
Stanford inventors have developed a functionally-graded implant device for the reconstitution of the necrotic area removed after surgical treatment of osteonecrosis of the hip.
To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.
Determining a patient's drug susceptibility is currently a lengthy process requiring hundred to millions of cells. Currently, these cells are labelled, frozen or otherwise manipulated in ways that prevent sequential testing against multiple drugs on the same few cells.
Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.
The Zhenan Bao Research Group at Stanford University developed and manufactured a photo-curable, directly patternable, stretchable, and highly conductive polymer that is ideal for bioelectronic applications, and stretchable electronic devices.